Value stocks aren't typically the most exciting investments, but they can often provide steady capital gains without causing investors to lose any sleep during periods of market volatility. Value ...

Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA ...

Merck (NYSE: MRK) is a top healthcare company with one of the best drugs ever made in its portfolio: Keytruda. During the ...

We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look ...

Multinational companies in China’s vaccine market face headwinds amid an anti-corruption crackdown and rising competition.

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

We recently published a list of 15 Best Defensive Stocks Amid Market Volatility In this article, we are going to take a look ...

NEW YORK, NY / ACCESS Newswire / March 25, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE:MRK) between February 3, 2022 and ...

Strong positive interim data from an earlier Phase 3 trial has led to early cessation of Merck’s pulmonary arterial ...

In addition to this, Moody’s upgraded Merck & Co., Inc.’s senior unsecured revolving credit facility to Aa3 from A1, and the senior unsecured shelf ratings of both Merck & Co., Inc. and MSD ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) and reminds investors of the April 14, ...

A class action lawsuit is brewing against Merck & Co. over claims of securities fraud, and investors aren’t exactly raising a ...